Consensus Ashland Inc.

Stocks

ASH

US0441861046

Diversified Chemicals

Market Closed - NYSE 06:00:03 16/09/26 am AEST			5-day change	1st Jan Change
70.27 ^USD	+0.86%		-3.24%	+19.77%

24/08	Ashland Inc. Launches Permexa Sodium Caprate to Support Scalable Development and Commercialization of Oral Peptide, Biologic and Low-Permeability Drug Products	CI
13/08	Ancora offers up to $1.2bn for an H.B. Fuller business

Evolution of the Average Target: Ashland Inc.

Evolution of the Target Price: Ashland Inc.

Changes in Analyst Recommendations: Ashland Inc.

0331fb07f7c02af.TmdsDcI9AEUDlfbG6koYvAM0Ad7-sgZmRvbInDNRojI.fisFfKxpYhEz4rj_ozJU9HoNcaiK-D5VNqW9qnUUkEQnNQtpl3dfNVPzzg~7fac0aae743452cda0b93f01840a7542

Analysts' recommendations: Ashland Inc.

07/08	Ashland's Fundamentals Appear to Improve With a Fiscal Q3 Beat, Morgan Stanley Says	MT
06/08	Morgan Stanley Adjusts Price Target on Ashland to $78 From $58, Maintains Equalweight Rating	MT
31/07	Deutsche Bank Adjusts Ashland Price Target to $85 From $74, Maintains Buy Rating	MT
31/07	UBS Adjusts Price Target on Ashland to $83 From $75, Maintains Buy Rating	MT
15/06	Deutsche Bank Adjusts Ashland Price Target to $74 From $60, Maintains Buy Rating	MT
10/06	UBS Lifts Ashland Price Target to $72 From $66, Maintains Buy Rating	MT
06/05	Seaport Upgrades Ashland to Buy From Neutral, Sets $75 Price Target	MT
05/05	Ashland's Fiscal Q2 a 'Mixed Bag' With Downward EBITDA Revisions, Morgan Stanley Says	MT
04/05	Morgan Stanley Lowers Price Target on Ashland to $58 From $63, Keeps Equalweight Rating	MT
06/04	Mizuho Cuts Price Target on Ashland to $65 From $70, Keeps Outperform Rating	MT
05/02	UBS Adjusts Price Target on Ashland to $73 From $70, Maintains Buy Rating	MT
05/02	Deutsche Bank Adjusts Ashland Price Target to $70 From $58, Maintains Buy Rating	MT
13/01	UBS Adjusts Price Target on Ashland to $70 From $64, Maintains Buy Rating	MT
19/12	Mizuho Securities Adjusts Ashland Price Target to $70 From $60, Maintains Outperform Rating	MT
16/12	Ashland Shares Rise After BMO Capital Upgrade	MT
16/12	BMO Capital Upgrades Ashland to Outperform From Market Perform, Adjusts PT to $71 From $61	MT
12/11	Deutsche Bank Raises Price Target on Ashland to $58 From $55, Keeps Buy Rating	MT
03/10/25	Mizuho Lowers Price Target on Ashland to $54 From $58, Keeps Outperform Rating	MT
30/09/25	Deutsche Bank Cuts Price Target on Ashland to $55 From $62, Keeps Buy Rating	MT
08/09/25	Morgan Stanley Initiates Coverage on Ashland With Equal Weight Rating, $60 Price Target	MT
08/08/25	UBS Adjusts Price Target on Ashland to $64 From $73, Maintains Buy Rating	MT
10/07/25	UBS Trims Price Target on Ashland to $73 From $74, Maintains Buy Rating	MT
02/05/25	Wells Fargo Downgrades Ashland to Equalweight From Overweight, Adjusts Price Target to $50 From $58	MT
02/05/25	UBS Adjusts Price Target on Ashland to $74 From $85, Maintains Buy Rating	MT
26/03/25	JPMorgan Upgrades Ashland to Overweight From Neutral, Adjusts Price Target to $71 From $68	MT

More recommendations

Diversified Chemicals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ASHLAND INC.					+14.11%
	SHIN-ETSU CHEMICAL CO., LTD.					+36.57%
	BASF SE					+1.32%
	PIDILITE INDUSTRIES LIMITED					+17.44%
	ASAHI KASEI CORPORATION					+25.21%
	BRENNTAG SE					-4.89%
	MITSUBISHI CHEMICAL GROUP CORPORATION					+11.71%
	SYENSQO SA/NV					+6.19%
	SASOL LIMITED					-11.34%
	SRF LIMITED					+18.9%
	Average					+11.52%
	Weighted average by Cap.					+17.06%